Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial-Reference-Cited by-同舟云学术

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Published:2021-11-17 Issue:1 Volume:11 Page:61-73
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Balasubramanian Sriram¹^ORCID,Hodkinson Brendan¹,Schuster Stephen J.²,Fowler Nathan H.³,Trotman Judith⁴,Hess Georg⁵,Cheson Bruce D.⁶,Schaffer Michael¹,Sun Steven⁷,Deshpande Sanjay⁷,Vermeulen Jessica⁸,Salles Gilles⁹,Gopal Ajay K.¹⁰¹¹

Affiliation:

1. Janssen Research & Development Spring House Pennsylvania USA

2. Lymphoma Program Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania USA

3. Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA

4. Haematology Department, Concord Hospital University of Sydney Sydney New South Wales Australia

5. Department of Hematology/Oncology Johannes Gutenberg‐University Mainz Germany

6. Lombardi Comprehensive Cancer Center Georgetown University Hospital Washington District of Columbia USA

7. Janssen Research & Development Raritan New Jersey USA

8. Janssen Research & Development Leiden The Netherlands

9. Hospices Civils de Lyon Université de Lyon Pierre‐Bénite Cedex, Lyon France

10. Division of Medical Oncology Department of Medicine The University of Washington Seattle Washington USA

11. Clinical Research Division Fred Hutchinson Cancer Research Center Lymphoma Program Seattle Cancer Care Alliance Seattle Washington USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4422

Reference48 articles.

1. Correction to: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

3. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology. B‐cell lymphomas. Version 4.2015. Available from:https://www.nccn.org/professionals/physician_gls/default.aspx

4. Unmet needs in the first-line treatment of follicular lymphoma

5. Individualized management of follicular lymphoma;Bai B;Chin Clin Oncol,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives for next generation sequencing in patients with follicular lymphoma;Oncohematology;2023-12-08

2. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial;Blood Advances;2023-05-11